Trial Profile
Maintenance Lenalidomide Therapy After Autologous Stem Cell Transplant in Patients With High Risk Relapsed/Refractory Lymphomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 23 Mar 2023 Status changed from active, no longer recruiting to completed.
- 03 Jun 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 16 Apr 2019 Planned End Date changed from 1 Apr 2016 to 31 Dec 2021.